Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Amortization of Deferred Charges (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Amortization of Deferred Charges for 7 consecutive years, with $29000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Amortization of Deferred Charges rose 3.57% to $29000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $111000.0, a 68.29% decrease, with the full-year FY2025 number at $108000.0, down 81.91% from a year prior.
  • Amortization of Deferred Charges was $29000.0 for Q4 2025 at Aytu Biopharma, roughly flat from $29000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $170000.0 in Q4 2022 to a low of -$165000.0 in Q4 2021.
  • A 5-year average of $56789.5 and a median of $98000.0 in 2023 define the central range for Amortization of Deferred Charges.
  • Peak YoY movement for Amortization of Deferred Charges: plummeted 451.06% in 2021, then skyrocketed 203.03% in 2022.
  • Aytu Biopharma's Amortization of Deferred Charges stood at -$165000.0 in 2021, then surged by 203.03% to $170000.0 in 2022, then dropped by 9.41% to $154000.0 in 2023, then tumbled by 81.82% to $28000.0 in 2024, then grew by 3.57% to $29000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Amortization of Deferred Charges are $29000.0 (Q4 2025), $29000.0 (Q3 2025), and $26000.0 (Q2 2025).